Stephen J. Tulipano
2023 - Stoke Therapeutics
In 2023, Stephen J. Tulipano earned a total compensation of $1.6M as Chief Financial Officer at Stoke Therapeutics, a 31% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $165,110 |
|---|---|
| Option Awards | $474,186 |
| Salary | $458,640 |
| Stock Awards | $489,272 |
| Other | $11,273 |
| Total | $1,598,481 |
Tulipano received $489.3K in stock awards, accounting for 31% of the total pay in 2023.
Tulipano also received $165.1K in non-equity incentive plan, $474.2K in option awards, $458.6K in salary and $11.3K in other compensation.
Rankings
In 2023, Stephen J. Tulipano's compensation ranked 740th out of 2,978 executives tracked by ExecPay. In other words, Tulipano earned more than 75.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 740 out of 2,978 | 75th |
Division Manufacturing | 422 out of 1,637 | 74th |
Major group Chemicals And Allied Products | 285 out of 906 | 69th |
Industry group Drugs | 279 out of 869 | 68th |
Industry Pharmaceutical Preparations | 184 out of 627 | 71st |
Source: SEC filing on April 23, 2024.
Tulipano's colleagues
We found two more compensation records of executives who worked with Stephen J. Tulipano at Stoke Therapeutics in 2023.